Loading clinical trials...
Loading clinical trials...
This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 alone or in combination with pegylated interferon alfa-2a and will be assessed for safety...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Vir Biotechnology, Inc.
Collaborators
NCT07417553 · Chronic Hepatitis B-related Liver Fibrosis
NCT02932150 · Chronic Hepatitis B
NCT06671093 · Chronic Hep B, Chronic Hepatitis b, and more
NCT05853718 · Chronic Hepatitis b, Tenofovir Alafenamide Fumarate
NCT06885710 · Chronic Hepatitis b
Investigative Site
Birtinya, Queensland
Investigative Site
Fitzroy, Victoria
Investigative site
Hong Kong
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions